Rectal Cancer Clinical Trial
Official title:
Fit for Surgery. Clinical Randomized Trial of Multimodal Prehabilitation Strategy in Patients With Colorectal Cancer.
Verified date | February 2022 |
Source | Zealand University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized clinical trial of multimodal prehabilitation in vulnerable patients with colon or rectal cancer prior to surgery.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | August 1, 2022 |
Est. primary completion date | May 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Undergoing elective colorectal cancer surgery - WHO performance status I and II - Signed consent Exclusion Criteria: - Known metastatic disease - Unable to perform baseline test or basic training e.g. paralytic or completely immobilized patients, orthopedic impairments. - ASA 4 or 5 (American Society of Anesthesiologist Classification) - Neoadjuvant chemo- or radiation therapy - Renal failure III B or higher - Illiteracy or unable to write or understand Danish - Cognitive disabilities, which affects adherence e.g. severe dementia (MMSE score =17). - Withdrawal of consent. |
Country | Name | City | State |
---|---|---|---|
Denmark | Zealand University Hospital | Køge | Danmark |
Denmark | Slagelse Hospital | Slagelse | Danmark |
Lead Sponsor | Collaborator |
---|---|
Zealand University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Recovery 15 | Difference in postoperative recovery between baseline and within 3 days after surgery. The cumulative score ranges from 0-150, with a higher value indicating a better outcome | 3 days after surgery | |
Primary | Changes in physical fitness prior to surgery | Changes in VO2 max between baseline and prior to surgery | Baseline, prior to surgery and 30 days after surgery | |
Primary | Complications | Complications measured by the comprehensive complication index. The score ranges from 0-100 with with a higher value indicating a worse outcome. | 30 days after surgery | |
Primary | Changes in immunological function | Changes in immunological function measured by nanostring in blood and tumor (in the invasive front) | Blood work taken at baseline, prior to surgery, three days after surgery and four weeks after surgery. Tumor from resectionspecimen | |
Secondary | Disease specific quality of life - EORTC c30 | European Organisation for Research and Treatment of Cancer Questionaire c 30 (EORTC c30). The EORTC c30 contains 6 domains which will each be assessed for mean changes in their cumulative score. The domains are physical function, role function, emotional function, pain, fatigue and global health. A higher value indicating a worse outcome | the day prior to surgery, 30 days after surgery, 60 days after surgery and one year after surgery | |
Secondary | Disease specfic quality of life - EORTC c29 | European Organisation for Research and Treatment of Cancer Questionaire c 29 (EORTC). The questionnaire contains 29 items, with a 4 point Likert scale for symptoms and 7 point Likert scale for quality of life and global health. For the 4 point Likert scale the higher the score the worse the outcome. For the 7 point likert scale higher values indicating a better outcome. Analysis will be performed for changes in individual symptoms and cumulative aggregation of scores will not be performed. | the day prior to surgery, 30 days after surgery, 60 days after surgery and one year after surgery | |
Secondary | Overall quality of life - SF-36 | Short Form 36 question (SF-36) health questionnaire. The questionnaire contains eight domains: physical functioning, pain, limitations due to physical health problems, limitations due to personal or emotional problems, emotional well-being, social functioning, fatigue, and general health perceptions. Scores for each domain range from 0 to 100 and the analysis will be performed as mean difference between baseline and the following time frame. A higher value indicating a better outcome. | the day prior to surgery, 30 days after surgery, 60 days after surgery and one year after surgery | |
Secondary | Psychological health - Depression - PHQ-9 | Patient Health Questionnaire 9 (PHQ-9) Depression test. The PHQ-9 have a maximum of 27 points and a minimum of 0. The outcome is point change between baseline and following time frame. A higher value indicating a worse outcome | the day prior to surgery,30 days after surgery, 60 days after surgery and one year after surgery | |
Secondary | Psychological health - General anxiety - GAD-7 | General Anxiety Disorder 7-item (GAD-7). The questionnaire have a maximum of 21 points and a minium of 0. The outcome is the point change between baselin and the following time frame. A higher value indicating a worse outcome | the day prior to surgery, 30 days after surgery, 60 days after surgery and one year after surgery | |
Secondary | Physical function (6-MWT) | 6-Minutes walk test. Measures how far the participant can walk in 6 minutes measured in meters | The day prior to surgery, 30 days after surgery, and 60 days after surgery | |
Secondary | Physical function (STS) | Sit-to-stand test. Test of how many times the patient can rise from a chair in 30 seconds. | The day prior to surgery, 30 days after surgery, and 60 days after surgery. | |
Secondary | Physical function (Stair climb test) | Stair climb test will be measured as the number of steps (17 mc in height) the paitent can rise in 30 secounds. | The day prior to surgery, 30 days after surgery, and 60 days after surgery | |
Secondary | Physical function (Leg extension test) | Leg extension test will be measured by fixed dynaometer in newtons three times on each leg and the maximum for each leg used for analysis. | The day prior to surgery, 30 days after surgery, and 60 days after surgery | |
Secondary | Physical function (Hand grip strength) | Hand grip strength measured by hand-held dynanometer in kilograms. Measured 3 times on each hand and will use the maximum obtained. | The day prior to surgery, 30 days after surgery, and 60 days after surgery | |
Secondary | Nutritional status | Increase/decrease in total body weight in percent. | The day prior to surgery, 30 days after surgery, and 60 days after surgery | |
Secondary | Remission and cancer free survival | Remission and cancer free survival | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |